QUANTUM BIOPHAR (QNTM)
(Delayed Data from NSDQ)
$5.50 USD
-0.04 (-0.72%)
Updated Oct 29, 2024 04:00 PM ET
After-Market: $5.44 -0.06 (-1.09%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
QNTM 5.50 -0.04(-0.72%)
Will QNTM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for QNTM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QNTM
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know
QNTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNTM
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
Quantum Group announces start of sentinel dosing in Lucid-21-302 MAD trial
Quantum retains services of Agoracom, ITG, Buyins and Stockjock
Quantum retains services of Agoracom, ITG, Buyins and Stockjock
Quantum Group announces start of sentinel dosing in Lucid-21-302 MAD trial